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The glycoproteins recognized by moAbs NKI-beteb 
(gp 100 and gp7) and HMB-45 (gplO) are amongst 
the best markers for human melanoma available to 
date. Although moAbs directed against these 
antigens are very suitable for diagnostic 
purposes, they are less suitable for therapeutic 
purposes since the antigens are primarily 
expressed intracellularly. However, peptides 
derived from the antigens, if presented by MHC 
molecules, may well be capable of evoking 
cellular immune responses.
Using a rabbit polyclonal antiserum against 
gplOO we isolated a cDNA clone containing an 
insert of 2.1 kb. This cDNA detected KNA species 
of 2.5 kb and 4.2 kb on Northern blots containing 
total RNA isolated from melanoma cells and 
melanocytes but not from any other cell type 
tested. Expression of the cDNA in either cos-7 
cells or gplOO negative melanoma cells resulted 
in NKI-beteb as well as HMB-4 5 immunoreactivity. 
This indicates that NKI-beteb and HMB-45 both 
recognize the protein(s) encoded by this cDNA. 
Biochemical characterisation of the protein 
recognized by NKI-beteb in transfected cos-7 
cells demonstrated that the cDNA clone encodes 
gplOO as well as gp7.
We are currently determining the sequence of 
this cDNA clone. In addition, we are generating 
CTLs which recognize peptides derived from gplOO 
in an MHC restricted manner. These CTls will be 
tested for anti-tumor activity in an in vivo 
model system.
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